Why safety reporting matters: from site reports to regulatory signals
Trace the path of adverse event reports from site documentation to regulatory signal detection, understanding why every CRC report matters for patient safety worldwide.
The withdrawal that changed everything
On 30 September 2004, Merck & Co. voluntarily withdrew rofecoxib -- marketed as Vioxx -- from the worldwide market. The drug had been prescribed to approximately 80 million people since its approval in 1999. The reason for withdrawal was unambiguous: data from the APPROVe trial (Adenomatous Polyp Prevention on Vioxx) demonstrated a statistically significant increase in cardiovascular events -- heart attacks and strokes -- in participants taking rofecoxib compared to placebo.